UPB
$9.71
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and c...
Recent News
Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56%
Upstream Bio (NASDAQ:UPB) reported top-line results from its Phase II VALIANT trial evaluating verekitug in adults with severe asthma, highlighting statistically significant reductions in annualized asthma exacerbation rate (AAER) with multiple dosing regimens and a safety profile the company said w
Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Upstream Bio’s stock drops 47% on verekitug Phase II asthma data
Investors pull away from Upstream as a twice-yearly dose of verekitug fails to match Tezspire’s efficacy in reducing asthma exacerbations.
Upstream Bio Crashes After Asthma Drug Succeeds — With The Wrong Dose
Shares of Upstream Bio crashed Wednesday after the biotech's asthma drug succeeded in Phase 2 study, but with a more frequent dosing regimen.
Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill
Shares of Evommune nearly doubled on data suggesting it has a potential threat to Dupixent. Elsewhere, a closely watched narcolepsy drug got an FDA decision date and investors scrutinized Upstream’s asthma results.